Clinical significance of serum procalcitonin in patients with ulcerative colitis

被引:20
|
作者
Koido, Shigeo [1 ]
Ohkusa, Toshifumi [1 ]
Takakura, Kazuki [1 ]
Odahara, Shunichi [1 ]
Tsukinaga, Shintaro [1 ]
Yukawa, Toyokazu [1 ]
Mitobe, Jimi [1 ]
Kajihara, Mikio [1 ]
Uchiyama, Kan [1 ]
Arakawa, Hiroshi [1 ]
Tajiri, Hisao [1 ]
机构
[1] Jikei Univ, Div Gastroenterol & Hepatol, Dept Internal Med, Sch Med, Kashiwa, Chiba 2778567, Japan
关键词
C-reactive protein; Disease activity; Procalcitonin; Severity; Ulcerative colitis; INFLAMMATORY-BOWEL-DISEASE; C-REACTIVE PROTEIN; BACTERIAL-INFECTION; CROHNS-DISEASE; SEPSIS; HYDROCORTISONE; THERAPY; MARKERS;
D O I
10.3748/wjg.v19.i45.8335
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
AIM: To investigate the association of procalcitonin (PCT) with ulcerative colitis (UC) activity. METHODS: Serum PCT levels, C-reactive protein (CRP) levels, the erythrocyte sedimentation rate, and the white blood cell count were analyzed in 18 patients with UC and 11 healthy volunteers. Serum PCT levels were analyzed by an electrochemiluminescence immunoassay. Severity assessments were based on Truelove and Witts' severity index. Correlation of serum PCT and CRP levels with UC activity was examined. Moreover, we assessed serum PCT and CRP levels in patients with a Mayo endoscopic subscore. RESULTS: Serum PCT levels in severe UC patients (n = 7) (0.096 +/- 0.034 ng/mL) were significantly higher than in mild-to-moderate UC patients (n = 11) (0.033 +/- 0.012 ng/mL) and healthy volunteers (n = 11) (0.035 +/- 0.005 ng/mL) (P = 0.0005 and P < 0.0001, respectively). In addition, there was no difference in serum PCT levels between mild-to-moderate UC patients and healthy volunteers. Interestingly, patients with a Mayo endoscopic subscore of 3 points displayed significantly increased levels of serum PCT (0.075 +/- 0.043 ng/mL) compared with patients with a subscore of 2 points (0.03 +/- 0.011 ng/mL) (P = 0.0302). Moreover, CRP levels in patients with severe UC or a Mayo endoscopic subscore of 3 points were not significantly higher than in patients with mild-to-moderate UC or a Mayo endoscopic subscore of 3 points. CONCLUSION: Serum PCT levels were significantly correlated with UC activity. (C) 2013 Baishideng Publishing Group Co., Limited. All rights reserved.
引用
收藏
页码:8335 / 8341
页数:7
相关论文
共 50 条
  • [31] Clinical significance of residual non-rectal inflammation in ulcerative colitis patients with clinical remission
    Shin, J.
    Seong, G.
    Song, J. H.
    Kong, S. M.
    Kim, T. J.
    Kim, E. R.
    Hong, S. N.
    Chang, D. K.
    Kim, Y. H.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S577 - S578
  • [32] IDENTIFICATION OF NOVEL SERUM BIOMARKERS FOR PREDICTION OF CLINICAL COURSE IN PATIENTS WITH ULCERATIVE COLITIS
    Hamanaka, Shinsaku
    Nakagawa, Tomoo
    Hiwasa, Takaki
    Ohta, Yuki
    Kasamatsu, Shingo
    Ishigami, Hideaki
    Taida, Takashi
    Okimoto, Kenichiro
    Saito, Keiko
    Maruoka, Daisuke
    Matsumura, Tomoaki
    Arai, Makoto
    Takizawa, Hirotaka
    Matsushita, Kazuyuki
    Katsuno, Tatsuro
    GASTROENTEROLOGY, 2017, 152 (05) : S775 - S776
  • [33] Serum Vitamin D and Risk of Clinical Relapse in Patients With Ulcerative Colitis Reply
    Gubatan, John Mark B.
    Moss, Alan C.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (07) : 1136 - 1137
  • [34] THE EFFECT OF TOFACITINIB ON SERUM LIPIDS AND CARDIOVASCULAR SAFETY IN PATIENTS WITH ULCERATIVE COLITIS - RESULTS FROM THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAM
    Sands, Bruce E.
    Taub, Pam R.
    Feagan, Brian G.
    Armuzzi, Alessandro
    Friedman, Gary S.
    Moscariello, Michele
    Lawendy, Nervin
    Pedersen, Ronald D.
    Chan, Gary
    Nduaka, Chudy I.
    Quirk, Daniel
    Salese, Leonardo
    Su, Chinyu
    GASTROENTEROLOGY, 2018, 154 (06) : S380 - S380
  • [35] The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: results from the tofacitinib ulcerative colitis clinical programme
    Sands, B. E.
    Taub, P. R.
    Feagan, B. G.
    Armuzzi, A.
    Friedman, G. S.
    Moscariello, M.
    Lawendy, N.
    Pedersen, R. D.
    Chan, G.
    Nduaka, C. I.
    Quirk, D.
    Salese, L.
    Su, C.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S23 - S23
  • [36] Clinical significance of serum procalcitonin and C-reactive protein in patients with septic shock
    Su, Songlin
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 13 (12): : 9600 - 9606
  • [37] Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients
    Kovacs, Gyorgy
    Sipeki, Nora
    Suga, Boglarka
    Tornai, Tamas
    Fechner, Kai
    Norman, Gary L.
    Shums, Zakera
    Antal-Szalmas, Peter
    Papp, Maria
    PLOS ONE, 2018, 13 (03):
  • [38] THE EFFECT OF TOFACITINIB ON SERUM LIPIDS AND CARDIOVASCULAR SAFETY IN PATIENTS WITH ULCERATIVE COLITIS - UPDATED RESULTS FROM THE TOFACITINIB ULCERATIVE COLITIS CLINICAL PROGRAM
    Sands, Bruce E.
    Taub, Pam R.
    Feagan, Brian G.
    Armuzzi, Alessandro
    Damiao, Aderson O.
    Lawendy, Nervin
    Solano, Gaston
    Kwok, Kenneth
    Woolcott, John
    Salese, Leonardo
    Su, Chinyu
    GASTROENTEROLOGY, 2020, 158 (06) : S1190 - S1190
  • [39] THE EFFECT OF TOFACITINIB ON SERUM LIPIDS AND CARDIOVASCULAR SAFETY IN PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM THE TOFACITINIB OCTAVE ULCERATIVE COLITIS CLINICAL PROGRAM
    Vermeire, Severine
    Armuzzi, Alessandro
    Kwok, Kenneth K.
    Lawendy, Nerrvin
    Woolcott, John
    Salese, Leonardo
    Su, Chinyu
    Hudesman, David
    GASTROENTEROLOGY, 2021, 160 (06) : S353 - S353
  • [40] The effect of tofacitinib on serum lipids and cardiovascular safety in patients with ulcerative colitis: updated results from the tofacitinib ulcerative colitis clinical programme
    Sands, B. E.
    Taub, P. R.
    Feagan, B. G.
    Armuzzi, A.
    Damiao, A. O.
    Lawendy, N.
    Solano, G.
    Kwok, K.
    Woolcott, J.
    Salese, L.
    Su, C.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S557 - S558